H W Jeong1, S-C Jin. 1. Department of Diagnostic Radiology, Busan Paik Hospital, Inje University, Busan, Korea.
Abstract
BACKGROUND AND PURPOSE:Abciximab and tirofiban are commonly used for the treatment of thromboembolisms that form during coiling of intracranial aneurysms; however, it is not known which of these inhibitors is safer and more effective. We report the safety and the recanalization rates for intra-arterial abciximab and intra-arterial tirofiban infusion for the treatment of thromboembolisms that form during coiling. MATERIALS AND METHODS:Between March 2004 and April 2011, 346 intracranial aneurysms were treated with coiling. Thromboembolisms developed in 22 of these patients and were treated by use of intra-arterial tirofiban (n = 11) or abciximab (n = 11) infusion. RESULTS: In the abciximab group, the thromboembolisms were completely (n = 1) or partially (n = 7) resolved in 8 cases (72.7%) at the time of the final control angiography. Complete (n = 9) or partial (n = 2) resolution was achieved in all cases at the time of follow-up angiography (<3 days after the procedure). In the tirofiban group, thromboembolisms were completely (n = 4) or partially (n = 6) resolved in 10 cases (90.9%) at the time of the final control angiography. Complete (n = 9) or partial (n = 2) resolution was observed in all cases at the time of the follow-up angiography. There were no statistically significant differences between the 2 groups with respect to thrombus resolution (final angiography, P = .311; follow-up angiography, P = .707). No hemorrhagic complications developed in either group. CONCLUSIONS: These results suggest that tirofiban is more effective than abciximab for the immediate resolution of thromboembolisms, with no statistical significance. Both intra-arterial tirofiban and abciximab exhibited similar safety and recanalization rates.
RCT Entities:
BACKGROUND AND PURPOSE:Abciximab and tirofiban are commonly used for the treatment of thromboembolisms that form during coiling of intracranial aneurysms; however, it is not known which of these inhibitors is safer and more effective. We report the safety and the recanalization rates for intra-arterial abciximab and intra-arterial tirofiban infusion for the treatment of thromboembolisms that form during coiling. MATERIALS AND METHODS: Between March 2004 and April 2011, 346 intracranial aneurysms were treated with coiling. Thromboembolisms developed in 22 of these patients and were treated by use of intra-arterial tirofiban (n = 11) or abciximab (n = 11) infusion. RESULTS: In the abciximab group, the thromboembolisms were completely (n = 1) or partially (n = 7) resolved in 8 cases (72.7%) at the time of the final control angiography. Complete (n = 9) or partial (n = 2) resolution was achieved in all cases at the time of follow-up angiography (<3 days after the procedure). In the tirofiban group, thromboembolisms were completely (n = 4) or partially (n = 6) resolved in 10 cases (90.9%) at the time of the final control angiography. Complete (n = 9) or partial (n = 2) resolution was observed in all cases at the time of the follow-up angiography. There were no statistically significant differences between the 2 groups with respect to thrombus resolution (final angiography, P = .311; follow-up angiography, P = .707). No hemorrhagic complications developed in either group. CONCLUSIONS: These results suggest that tirofiban is more effective than abciximab for the immediate resolution of thromboembolisms, with no statistical significance. Both intra-arterial tirofiban and abciximab exhibited similar safety and recanalization rates.
Authors: M T Roe; C B Granger; J A Puma; A S Hellkamp; J S Hochman; E M Ohman; H D White; F Van de Werf; P W Armstrong; S G Ellis; R M Califf; E J Topol Journal: Am J Cardiol Date: 2001-12-15 Impact factor: 2.778
Authors: Howard C Herrmann; Tomasz A Swierkosz; Shiv Kapoor; Danielle C Tardiff; Peter M DiBattiste; John W Hirshfeld; Bruce D Klugherz; Daniel M Kolansky; Kathleen Magness; Nicholas Valettas; Robert L Wilensky Journal: Am J Cardiol Date: 2002-06-01 Impact factor: 2.778
Authors: R Bruening; S Mueller-Schunk; D Morhard; K C Seelos; H Brueckmann; R Schmid-Elsaesser; A Straube; T E Mayer Journal: AJNR Am J Neuroradiol Date: 2006 Jun-Jul Impact factor: 3.825
Authors: Joon K Song; Yasunari Niimi; Patricia M Fernandez; Jonathan L Brisman; Razvan Buciuc; Mark J Kupersmith; Alejandro Berenstein Journal: AJNR Am J Neuroradiol Date: 2004-08 Impact factor: 3.825
Authors: Samuel Pearce; Julian T Maingard; Hong Kuan Kok; Christen D Barras; Jeremy H Russell; Joshua A Hirsch; Ronil V Chandra; Ash Jhamb; Vincent Thijs; Mark Brooks; Hamed Asadi Journal: Clin Neuroradiol Date: 2021-03-01 Impact factor: 3.649
Authors: J A Larco; M Abbasi; Y Liu; D Dai; G Lanzino; L E Savastano; H Cloft; D F Kallmes; R Kadirvel; W Brinjikji Journal: AJNR Am J Neuroradiol Date: 2021-12-16 Impact factor: 3.825